Bristol Myers Squibb (BMY) Non-Current Deffered Revenue (2009 - 2019)

Bristol Myers Squibb (BMY) has reported Non-Current Deffered Revenue for 11 consecutive years, with $448.0 million the latest figure, recorded in Q1 2019.

• On a quarterly basis, Non-Current Deffered Revenue changed 0.22% year-over-year to $448.0 million in Q1 2019; TTM through Mar 2019 was $448.0 million, a 0.22% change from a year earlier, with the FY2018 full-year figure at $468.0 million, up 3.08% from the prior year.
• Non-Current Deffered Revenue was $448.0 million for Q1 2019 at Bristol Myers Squibb, down from $468.0 million in the prior quarter.
• Over five years, Non-Current Deffered Revenue peaked at $697.0 million in Q1 2015 and troughed at $447.0 million in Q1 2018.
• A 5-year average of $542.5 million and a median of $528.0 million in 2017 frame the typical range for Non-Current Deffered Revenue.
• Across the five-year window, Non-Current Deffered Revenue slumped 35.99% in 2015 and increased 3.08% in 2018, its largest moves.
• Over 5 years, Non-Current Deffered Revenue stood at $586.0 million in 2015, then dropped by 6.66% to $547.0 million in 2016, then slipped by 17.0% to $454.0 million in 2017, then increased by 3.08% to $468.0 million in 2018, then slipped by 4.27% to $448.0 million in 2019.
• The last three Non-Current Deffered Revenue figures came in at $448.0 million (Q1 2019), $468.0 million (Q4 2018), and $486.0 million (Q3 2018), per Business Quant data.